1 Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for

- 2 skipping of exon 44 in patients with Duchenne muscular dystrophy: study
- 3 protocol for a phase I/II clinical trial
- 4
- 5 Takami Ishizuka^{1†}, Hirofumi Komaki^{1,2†}, Yasuko Asahina¹, Harumasa Nakamura¹, Norio
- 6 Motohashi³, Eri Takeshita², Yuko Shimizu-Motohashi², Akihiko Ishiyama², Chihiro
- 7 Yonee⁴, Shinsuke Maruyama⁴, Eisuke Hida⁵, Yoshitsugu Aoki^{3*}

8

9 Author details

- 10 ¹Clinical Research and Education Promotion Division, National Center Hospital,
- 11 National Center of Neurology and Psychiatry, Tokyo, Japan. ²Department of Child
- 12 Neurology, National Center Hospital, National Center of Neurology and Psychiatry,
- 13 Tokyo, Japan. ³Department of Molecular Therapy, National Institute of Neuroscience,
- 14 National Center of Neurology and Psychiatry, Tokyo, Japan. ⁴Department of Pediatrics,
- 15 Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima
- 16 City, Kagoshima, Japan. ⁵Department of Biostatistics and Data Science, Graduate
- 17 School of Medicine, Osaka University, Osaka, Japan.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18

19 Author emails

- 20 Takami Ishizuka: ishizukatakami@ncnp.go.jp
- 21 Hirofumi Komaki: komakih@ncnp.go.jp
- 22 Yasuko Asahina: asahina-yasuko@pmda.go.jp
- 23 Harumasa Nakamura: hnakamura@ncnp.go.jp
- 24 Norio Motohashi: nmotohashi@ncnp.go.jp
- 25 Eri Takeshita: erit@ncnp.go.jp
- 26 Yuko Shimizu-Motohashi: ymotohashi@ncnp.go.jp
- 27 Akihiko Ishiyama: ishiyama@ncnp.go.jp
- 28 Chihiro Yonee: komesogun@kufm.kagoshima-u.ac.jp
- 29 Shinsuke Maruyama: s-maru@m.kufm.kagoshima-u.ac.jp
- 30 Eisuke Hida: e-hida@bsds.med.osaka-u.ac.jp
- 31 Yoshitsugu Aoki: tsugu56@ncnp.go.jp
- 32

33 *Correspondence:

- 34 Yoshitsugu Aoki, 4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8551, Japan. Tel:
- 35 +81423412711. Fax: +81423461750. Email: tsugu56@ncnp.go.jp. ORCID iD: 0000-
- 36 0002-9038-7506.
- 38 [†]Takami Ishizuka and Hirofumi Komaki shared first authorship.

- .0

50

51 Abstract

- 52 **Aim:** The purpose of this study is to evaluate the safety and pharmacokinetics of the
- 53 novel morpholino oligomer NS-089/NCNP-02 which can induce exon 44 skipping, in
- 54 patients with DMD. Additionally, we aimed to identify markers predictive of therapeutic
- 55 efficacy and determine the optimal dosing for future studies.
- 56 **Methods:** This is an open-label, dose-escalation, two-center phase I/II trial in ambulant
- 57 patients with DMD, presence of an out-of-frame deletion, and a mutation amenable to
- 58 exon 44 skipping. Part 1 is a stepwise dose-finding stage (4 weeks) during which NS-
- 59 089/NCNP-02 will be administered intravenously at four dose levels once weekly (1.62,
- 10, 40, and 80 mg/kg); Part 2 is a 24-week evaluation period based on the dosages
- 61 determined during Part 1. The primary (safety) endpoints are the results of physical
- 62 examinations, vital signs, 12-lead electrocardiogram and echocardiography tests, and
- 63 adverse event reporting. Secondary endpoints include expression of dystrophin protein,
- 64 motor function assessment, exon 44 skipping efficiency, plasma and urinary NS-
- 65 089/NCNP-02 concentrations, and changes in blood creatine kinase levels.
- 66 **Discussion:** Exon-skipping therapy using ASOs shows promise in selected patients,

- 67 and this first-in-human study is expected to provide critical information for subsequent
- 68 clinical development of NS-089/NCNP-02.
- 69 Keywords: Antisense oligonucleotide, DMD, Duchenne muscular dystrophy, Exon-
- 70 skipping, Exon 44, First-in-human study, NS-089/NCNP-02, Pharmacokinetics, Safety,
- 71 Study protocol.
- 72

73 Background

74	Globally, the X-linked recessive disorder Duchenne muscular dystrophy (DMD) is
75	reported to occur with a birth prevalence of 19.8 per 100,000 males [1]. DMD is the
76	most common form of childhood-onset muscular dystrophy, caused by mutations in the
77	DMD gene that result in absent or insufficient levels of the functional cytoskeletal
78	protein dystrophin [2]. This underlying pathophysiology results in progressive muscular
79	degeneration and damage and, ultimately, early mortality [3].
80	Owing to its chromosomal localization, DMD predominantly affects male children,
81	while females are generally (although not exclusively) asymptomatic carriers [4].
82	Clinical symptoms include muscle weakness and degeneration in early childhood; the
83	diagnosis of DMD was based on the results of genetic analysis by multiplex ligation-

84	dependent probe amplification (MLPA) and direct sequencing of the DMD gene [3]. By
85	the age of 12, individuals with DMD are typically non-ambulant. They require a
86	wheelchair [2] and commonly develop additional orthopedic problems such as scoliosis
87	[5]. This, in turn, can lead to chest cavity reduction and respiratory dysfunction [2]. The
88	development of cardiomyopathy in young adulthood may cause additional breathing
89	difficulties [6]. As a result, for most individuals with DMD, the average life expectancy is
90	approximately 30 years [3].
91	Until now, many available treatments (e.g., surgery for spinal deformity, cardiac
92	failure management, respiratory support, physiotherapy) addressed only the symptoms
93	of DMD and were able to slow the course of the disease but could not halt the
94	progressive muscle loss [7]. The only accepted disease-modifying treatment has been
95	the use of corticosteroids, which can suppress muscle inflammation; however, the
96	efficacy of corticosteroid treatment is limited and side effects can be considerable [8, 9].
97	Based on the clear need for improved disease-modifying treatments for DMD,
98	several radical therapies have been studied in recent years, including gene therapy
99	and stem cell transplantation [10]. Exon-skipping therapy, which induces an in-frame
100	mutation in mature messenger RNA (mRNA) with sequence-specific antisense
101	oligonucleotides (ASOs), is of particular interest to DMD researchers and clinicians [7,

102	11]. Exon skipping aims to mask specific exons in the DMD gene transcripts, thereby
103	overcoming the out-of-frame mutation that underlies DMD and restoring the expression
104	of a shorter but functional dystrophin protein [12-14]. In-frame deletions result in the
105	production of truncated dystrophin, which translates into a less severely affected
106	Becker muscular dystrophy (BMD). Several exon-skipping therapeutic options have
107	now been approved for use in the United States (US), although their availability
108	elsewhere differs. Eteplirsen (Exondys 51) is an exon 51-skipping ASO that was
109	approved to treat patients with DMD by the Food and Drug Administration (FDA) in the
110	US in 2016 [15]; however, it has not yet been approved by the European Medicines
111	Agency for use in Europe. Golodirsen (Vyondys 53) is an exon 53-skipping ASO
112	approved by the FDA in 2019 [16]. Viltolarsen (NS-065/NCNP-01; Viltepso) is another
113	exon 53-skipping ASO, and this treatment was approved in 2020 by both the FDA [17]
114	and the Japanese Pharmaceuticals and Medical Devices Agency [18].
115	Viltolarsen (NS-065/NCNP-01) was discovered and developed by the National
116	Center of Neurology and Psychiatry (NCNP) in collaboration with Nippon Shinyaku Co.,
117	Ltd. In preclinical studies, this morpholino oligomer was found to promote skipping of
118	exon 53 in a dose-dependent manner and restore dystrophin protein levels in patient-
119	derived cells [19]. Based on the reported locations of mutations in the DMD gene, it

120	was anticipated that NS-065/NCNP-01 could benefit the 6%–9.4% of patients with
121	DMD amenable to exon 53 skipping [20], and early-stage clinical development began in
122	2016 [21]. Based on positive phase II data [22], the FDA granted conditional approval
123	to viltolarsen in 2020, pending the ongoing phase III RACER53 trial [23].
124	Subsequently, the NCNP researchers and Nippon Shinyaku Co., Ltd. are
125	collaborating to develop another novel morpholino oligomer, NS-089/NCNP-02, which
126	induces exon 44 skipping to correct the open reading frame. This exon was selected
127	because the neighboring exon 45 is the single exon most commonly deleted [24]; in
128	theory, in patients with exon 45 mutations, skipping of exon 44 should restore the open
129	reading frame to allow translation of a partially functional dystrophin protein and result
130	in less severe disease [24]. It will be anticipated that NS-089/NCNP-02 could benefit
131	the 7%–11% of patients with DMD amenable to exon 44 skipping [25]. To verify the
132	exon-skipping efficiency of NS-089/NCNP-02 in cells derived from DMD patients,
133	primary fibroblasts were obtained from patients with DMD amenable to exon 44
134	skipping. After patient fibroblasts were transfected with the human MYOD gene to
135	induce differentiation into myotubes, the myotubes were treated with NS-089/NCNP-02
136	in the presence of Endo-Porter as a delivery agent, and the effects of exon 44 skipping
137	were measured by RT-PCR 2 days after the start of treatment. We confirmed NS-

138	089/NCNP-02 induced efficient exon 44 skipping in cells from a patient with a deletion
139	of exons 45 or exons 45-54 (i.e., a complete inability to produce functional dystrophin)
140	(NCNP and Nippon Shinyaku Co., Ltd., data on file). Based on these results, there is
141	an expectation that NS-089/NCNP-02 could induce dystrophin expression and
142	suppress disease progression in patients amenable to exon 44 skipping (under review).
143	For trials of radical therapies in DMD, there is still an ongoing debate about the best
144	method for showing clinical benefit [7, 26]. In general, the usefulness of an exon-
145	skipping drug should be based on demonstrating its exon-skipping efficiency and its
146	effect on dystrophin restoration. Thus, we planned this phase I/II study to undertake an
147	early-phase clinical evaluation of NS-089/NCNP-02 in a limited number of patients.
148	One of the specific objectives of this study was to assess the potential utility of NS-
149	089/NCNP-02 as a drug for the treatment of patients with DMD by evaluating its safety
150	and pharmacokinetics (PK) (manuscript in preparation). Additionally, we aimed to
151	identify markers predictive of therapeutic efficacy and determine the optimal dosing for
152	future studies.

153

154 Methods/design

155 Study design and setting

156	This is an open-label, dose-escalation, two-center phase I/II trial. The study is
157	registered at clinicaltrials.gov under the identifier NCT04129294 and with the University
158	hospital Medical Information Network as UMIN000038505. The study has been
159	conducted at the NCNP (Tokyo, Japan) since 2 December 2019 and at Kagoshima
160	University Hospital (Kagoshima, Japan) since January 2021, and the study was
161	completed in 31 May 2022. The study site will be responsible for compensation in the
162	event of a health injury that occurs to a subject as a result of participating in the present
163	study. Any protocol modifications or amendments will require approval from the
164	Institutional Review Board.
165	The trial was designed in two parts. Part 1 is a stepwise dose-finding stage (4
166	weeks). Part 2 is a 24-week evaluation period based on the dosages determined during
167	Part 1. Interim assessments by the safety monitoring committee are planned to decide
168	whether to transition between dose levels in Part 1 and proceed from Part 1 to Part 2;
169	the relevant criteria are described in Table 1 .
170	

171 Study population

172	Patients enrolled in the study will be assigned subject identification codes to ensure
173	subject confidentiality, and these codes will be used in case report forms and all
174	documents related to the conduct of the study.
175	The study population will include ambulant patients (although non-ambulant patients
176	may be enrolled depending on enrollment status) with DMD, presence of an out-of-
177	frame deletion (confirmed by MLPA), and a dystrophin mutation amenable to exon 44
178	skipping (confirmed by direct sequencing). The key inclusion criteria are male patients
179	who are \ge 4 and < 17 years of age at the time of obtaining informed consent and who
180	have a life expectancy of \geq 1 year; presence of an out-of-frame deletion (confirmed by
181	MLPA) that can be restored to an in-frame deletion by exon 44 skipping of the DMD
182	gene; ability to undergo muscle biopsy (i.e., lacking severe atrophy of the biceps
183	brachii muscle or tibialis anterior muscle); corrected QT interval (QTc) < 450 msec on
184	standard 12-lead electrocardiogram (ECG) (based on Fridericia's formula), or QTc <
185	480 msec for patients with bundle branch block; and systemic corticosteroid therapy (if
186	any) started \geq 6 months prior to enrollment with the dosage unchanged within 3 months
187	of enrollment.

The study exclusion criteria include participation in any other clinical trial designed to
 restore the expression of dystrophin protein or related substances, or receipt of any

190	other investigational drug within 3 months before the start of administration of NS-
191	089/NCNP-02; impaired respiratory function to the extent that continuous use of a
192	ventilator (excluding non-invasive positive pressure ventilation while sleeping) is
193	necessary; a forced vital capacity of < 50% of the predicted value (based on the
194	reference values for spirometry in Japanese children [27]), a left ventricular ejection
195	fraction of < 40%, or fractional shortening of < 25% by ECHO; presence of any
196	immunodeficiency, autoimmune disease, active or uncontrolled infection,
197	cardiomyopathy, hepatic disease, renal disease, a positive test result for hepatitis B
198	virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus
199	antibody; any recent (within 3 months of enrollment) or planned surgery; a history of
200	serious hypersensitivity reactions to pharmacologic drugs; and any patient unable to
201	comply with the study procedures due to cognitive challenges or any patient whose
202	safety might be compromised by study participation.
203	

204 Study treatment

205 During the study, NS-089/NCNP-02 is planned to be administered at four dose levels

206 (1.62 mg/kg once weekly [QW], 10 mg/kg QW, 40 mg/kg QW, and 80 mg/kg QW).

207 Dosing Level 1 (1.62 mg/kg QW) was selected as the first dose based on the results of

208	animal toxicity studies (NCNP and Nippon Shinyaku Co., Ltd., data on file). Dosing
209	Level 4 (80 mg/kg QW) was calculated based on a combination of data from the toxicity
210	studies in animals (NCNP and Nippon Shinyaku Co., Ltd., data on file) and PK
211	inferences from the related morpholino oligomer viltolarsen (NS-065/NCNP-01)
212	administered at a dose of 80 mg/kg in humans [21]. The area under the plasma
213	concentration-time curve from 0–24 hours (AUC $_{0-24}$) when viltolarsen was administered
214	at 80 mg/kg in humans did not exceed that of NS-089/NCNP-02 administered at the
215	maximum tolerated dose in animals. It was, therefore, considered possible to
216	administer NS-089/NCNP-02 at a dose of up to 80 mg/kg QW. NS-089/NCNP-02 will
217	be administered intravenously over 1 hour (± 10 minutes).

218

219 Study procedures

220 In Part 1 of the study, Cohort 1 (three patients) will initially receive NS-089/NCNP-02 at 221 dosing Level 1 (1.62 mg/kg QW) for two weeks and at dosing Level 3 thereafter (40 222 mg/kg QW) for two weeks (Figure 1). Cohort 2 (three patients) will initially receive NS-223 089/NCNP-02 at dosing Level 2 (10 mg/kg QW) for two weeks and at dosing Level 4 224 thereafter (80 mg/kg QW) for two weeks. In Part 2 of the study, two different doses of 225 NS-089/NCNP-02 (determined from the results of Part 1) will be intravenously

226	administered QW for 24 weeks. Patients who have completed Part 1 are allowed to
227	participate in Part 2. A muscle biopsies will be performed twice, at the beginning of Part
228	1 and at the end of Part 2.
229	If a patient discontinues, an additional subject will be added to evaluate three
230	patients at each dose level. The second patient at each dose level in Part 1 will start
231	receiving NS-089/NCNP-02 after the second administration of NS-089/NCNP-02 in the
232	first patient. An interval of at least 4 weeks was mandated between dose levels in each
233	cohort.
234	Physiotherapy or exercise therapy regimens must be continued without change
235	between 90 days before starting the treatment and the end of the treatment period at
236	Part 2; no new therapies can be initiated during the study period. Pre-existing
237	concomitant drugs (including steroids) may be used between enrollment and the end of
238	the treatment period at Part 2. Other investigational drugs, adenosine-triphosphate
239	products, idebenone, and other coenzyme Q10 products will be prohibited.
240	The schedule of observations and examinations is shown in Figure 2 .
241	

242 Study endpoints

243	The primary (safety)	endpoints are the	results of physical	examinations,	vital signs,	12-
-----	----------------------	-------------------	---------------------	---------------	--------------	-----

- 244 lead ECG, echocardiography tests, and adverse event (AE) reporting. Measures
- include *DMD* gene tests (MLPA analysis), exon 44 sequencing analysis (by polymerase
- chain reaction using genome DNA derived from peripheral venous blood), hematology,
- 247 blood chemistry, urinalysis, cytokine/complement levels (Table 2), immunology tests,
- and pulmonary function tests. AEs and adverse drug reactions (ADRs) will be coded
- using the Medical Dictionary for Regulatory Activities version 23.1. Blood samples,
- 250 muscle tissues, dermal fibroblasts, and urine-derived cells collected will be anonymized
- and stored at a genetic testing laboratory or NCNP with no time limit.
- 252 Planned secondary endpoints include dystrophin protein expression (by western blot
- analysis), motor function assessment, exon 44 skipping efficiency, plasma and urinary
- 254 NS-089/NCNP-02 concentrations, and changes in blood creatine kinase levels. Motor
- 255 function assessments include the North Star Ambulatory Assessment score [28]; the
- time to stand from supine test [29]; the 10-meter walk/run test [30]; the 6-minute walk
- test [31]; the 2-minute walk test [32]; the timed "up & go" test [33]; quantitative muscle
- strength assessment (knee flexion/extension, elbow flexion/extension, and shoulder
- abduction); and grip strength, pinch strength, and upper limb performance assessed
- using the Performance of the Upper Limb module for DMD [34].

261	Additional study	examinations inclu	ided skeletal	muscle magnetic	resonance

- imaging (to determine the amount of muscle that can be biopsied); in vitro assays using
- 263 MYOD-transduced urine-derived cells (MYOD-UDCs), dermal MYOD-fibroblasts, and
- 264 myoblasts derived from the six enrolled subjects in the trial, evaluated by dystrophin
- 265 RT-PCR and western blot analysis; and plasma and urinary PK parameters. The
- timings of the blood and urine collections are shown in Additional file 1. NS-
- 267 089/NCNP-02 concentration and PK parameters will be measured by high-performance
- 268 liquid chromatography with tandem mass spectrometry.
- 269

270 Statistical analysis

271 The sample size in each study part was set at six patients. This sample size was

272 determined based on the feasibility of enrollment and motor function assessment at a

- 273 single center. No statistical significance was considered for the determination of sample
- size. Data will be assessed in three analysis sets (safety, efficacy, and PK). The safety
- analysis set will include all patients treated at least once with NS-089/NCNP-02. The
- 276 efficacy and PK analysis sets will include all patients enrolled, excluding those who
- 277 have a serious eligibility violation and those who lack the applicable data.

278	Patient demographic data will be tabulated using summary statistics. The primary
279	analysis (safety evaluation) will include tabulation of AEs and ADRs by number and
280	frequency and graphical representation of changes from baseline in vital signs, mean
281	laboratory test values, ECG, echocardiography, and pulmonary function parameters.
282	The efficacy and PK analyses will include an itemization of motor function testing and
283	calculation of NS-089/NCNP-02 exposure (including the maximum plasma
284	concentration $[C_{max}]$ and AUC ₀₋₂₄), half-life, systemic clearance, and distribution volume.
285	Analyses will also include tabulation of administration of NS-089/NCNP-02 (number of
286	administrations and exposure level by dose in each of the study parts). Analyses will be
287	conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA) and
288	Microsoft Excel 2016/2019.
289	
290	Data control and dissemination

All data and processes will be audited by independent monitors. The study data will be
published in peer-reviewed journals, using anonymized information to preserve patient
confidentiality.

295 Discussion

- 296 This is an exploratory phase I/II study of NS-089/NCNP-02. The protocol is reported
- 297 according to the Standard Protocol Items: Recommendation for Interventional Trials
- 298 (SPIRIT) 2013 Checklist (Additional File 2).
- 299 DMD is a disease with a significant impact on life expectancy, and although radical
- 300 therapies are being investigated, these generally involve complex procedures and
- 301 other challenges. Exon-skipping therapy using ASOs is a treatment that shows promise
- 302 in selected patients. This first-in-human study is expected to provide critical information
- 303 for subsequent clinical development of NS-089/NCNP-02, with the ultimate aim of
- 304 expanding the treatment armamentarium for affected patients.
- 305 In this study, the in vitro assay, which includes the differentiation of urine-derived
- 306 cells into myocytes, is based on the authors' recently published technique to create a
- 307 novel DMD muscle cell model [35]. This method could be used to screen different
- 308 ASOs prior to commencing clinical trials [20, 36], potentially streamlining the
- 309 therapeutic development process and reducing the time to availability of new treatment
- 310 strategies. Recently, we have reported an efficient cellular skeletal muscle modeling in
- 311 DMD using MYOD-UDCs obtained from DMD patients [35]. UDCs might be an ideal
- 312 cellular model for neuromuscular diseases because they have the high proliferative

313	ability and can be collected non-invasively. However, only a few studies are conducted
314	on MYOD-UDCs, it is desirable to use them in parallel with the well-characterized
315	MYOD-fibroblasts model [36]. Very recently, we, for the first time, evaluated the
316	usefulness of MYOD-UDCs from study subjects to evaluate the efficacy of NS-
317	089/NCNP-02 in the DMD clinical trial. We confirmed the drug's dose-dependent exon
318	44 skipping and dystrophin protein recovery in MYOD-UDCs obtained from all the
319	subjects (manuscript in preparation).
320	The modelling of truncated dystrophin protein lacking exons 44-45 or 45-46 predicts
321	that both should result in comparable stable hybrid rod structure, suggesting that, in
322	patients with exon 45 mutations, skipping of exon 44 or exon 46 should be excellent
323	therapeutic strategies [24]. However, it is already known that the resulting protein is
324	functional enough to maintain a mild BMD phenotype, which generally has mutations in
325	the DMD gene that maintain the open reading frame, allowing the production of
326	dystrophin proteins and thus are partially functional [38]. A documented example of this
327	is the spontaneous skipping of exon 44 that occurs when the exons flanking it are
328	deleted [39, 40]. Importantly, deletions amenable to exon 44 skipping are usually
329	associated with more dystrophin-revertant fibers and milder DMD phenotypes [41-43].
330	As the stability of the dystrophin transcript is a key indicator of dystrophin expression,

331	additional clinical exploration is warranted to discern whether transcript instability in
332	DMD compared with BMD could be a potential biomarker of response to ASOs [38].
333	Potential study limitations include the small sample size and open-label design,
334	limiting the conclusions that can be drawn. Then, significant challenges about ASOs
335	are the difficulty in selecting an optimal sequence for exon-skipping drug, identifying
336	biomarkers of treatment effect, large-scale pharmaceutical synthesis, and
337	pharmaceutical marketing. Other limitations are the requirement for more sensitive
338	outcome measures to quantify disease severity and our current incomplete
339	understanding of the long-term natural history of DMD in ambulant patients with
340	mutations amenable to exon 44 skipping.
341	The duration of the Part2 is short for identify the predictive efficacy, although the
342	progression of DMD in exon 44-skipped patients is relatively slow. Then, the long-term
343	extension study for 72 weeks is ongoing by our collaborator Nippon Shinyaku
344	(NCT05135663).
345	In summary, in this phase I/II study, we plan to assess the safety and PK of the
346	novel morpholino oligomer, NS-089/NCNP-02, which induces exon 44 skipping in the
347	DMD gene. These data will allow us to determine the optimal dosage for future clinical
348	development and provide the first indication of therapeutic efficacy. As such, the safety,

- 349 efficacy, and dosing analyses of this study are critical precursors to undertaking later
- 350 phase studies of NS-089/NCNP-02.
- 351
- 352 Trial status
- 353 The study was completed on 31 May 2022. The first patient was included on 2
- 354 December 2019. Enrollment is now finished, with the final patient's enrollment on 24
- 355 March 2020. The current article is based on protocol version 12.0, prepared on 11
- 356 November 2021.
- 357
- 358 Supplementary Information
- 359 File name: Additional file 1
- 360 File format: .doc
- 361 Title: Collection of blood and urine for measurement of NS-089/NCNP-02
- 362 concentration and PK parameters.
- 363 **Description:** This table shows the timings of the blood and urine collections.

- 365 File name: Additional file 2
- 366 File format: .doc
- 367 **Title:** SPIRIT checklist.

368

369 Abbreviations

- 370 ADR: adverse drug reaction; AE: adverse event; ASO: antisense oligonucleotide;
- 371 AUC₀₋₂₄: area under the plasma concentration-time curve from 0–24 hours; BMD:
- 372 Becker muscular dystrophy; C_{max}: maximum plasma concentration; DMD: Duchenne
- 373 muscular dystrophy; ECG: electrocardiogram; ECHO: echocardiogram; FDA: Food and
- 374 Drug Administration; MLPA: multiplex ligation-dependent probe amplification; mRNA:
- 375 messenger ribonucleic acid; NCNP: National Center of Neurology and Psychiatry; PK:
- 376 pharmacokinetics; QTc: corrected QT interval; QW: once weekly; US: United States.

377

378 Acknowledgments

- 379 The authors would like to thank the patients and their families for participating in this
- 380 study. The authors also thank Sally-Anne Mitchell, PhD, of Edanz Pharma for providing
- 381 medical writing services funded by Nippon Shinyaku Co., Ltd., Kyoto, Japan.

- 383 Disclosure
- 384 Conflict of interest
- 385 TI declares that there is no conflict of interest.
- 386 HK has received grants from Taiho, Pfizer, Nippon Shinyaku, Daiichi Sankyo, Chugai,
- 387 and PTC Therapeutics; and personal fees from Sarepta Therapeutics, Nippon
- 388 Shinyaku, Daiichi Sankyo, Kaneka, and Astellas.
- 389 YAs declares that there is no conflict of interest.
- 390 HN has received grants from Pfizer, Nippon Shinyaku, Daiichi Sankyo, and Astellas.
- 391 NM declares that there is no conflict of interest.
- 392 ET has received grants from Nippon Shinyaku, Taiho, Takeda, and Daiichi Sankyo.
- 393 YSM declares that there is no conflict of interest.
- 394 Al declares that there is no conflict of interest.
- 395 CY declares that there is no conflict of interest.
- 396 SM declares that there is no conflict of interest.
- 397 EH declares that there is no conflict of interest.

- 398 YAo reports receiving grants for joint research and researchers from Nippon Shinyaku
- 399 Co., Ltd.
- 400 This research was supported by the Japan Agency for Medical Research and
- 401 Development (Grant number 20Im0203086h0002) and an Intramural Research Grant
- 402 (Grant number 2-6) from the National Center of Neurology and Psychiatry. Nippon
- 403 Shinyaku Co., Ltd. Kyoto Japan provided investigational drugs. The study was
- 404 designed and conducted, analyzed, and interpreted by the investigators independently
- 405 of Nippon Shinyaku Co., Ltd.
- 406

407 Data Availability Statement

408 The datasets are available from the corresponding author upon reasonable request.

409

410 Approval of the research protocol by an Institutional Reviewer Board

- 411 This study is being conducted in compliance with the ethical principles that have their
- 412 origin in the Declaration of Helsinki and all applicable Japanese local and national
- 413 regulatory laws. The protocol and related documentation were approved by the
- 414 Institutional Review Board of the NCNP (approval number II-012).

415

416 Informed Consent

- 417 Legal representatives for each patient provided written informed consent prior to study
- 418 participation, and patients provided voluntary assent where possible.

419

420 Registry and the Registration No. of the study/trial

- 421 This study was registered at clinicaltrials.gov (NCT04129294) and with the University
- 422 Hospital Medical Information Network (UMIN000038505).

423

424 Authors' contributions

425	TI, HK, YAs, HN	, and YAo conceive	d and designed the	e study and were	involved in
	, , , ,	,	J	,	

- 426 protocol development. TI, YAs, and HN coordinated the regulatory aspects. ET, YSM,
- 427 AI, CY and SM were responsible for data acquisition. TI, HK, and EH were responsible
- 428 for data analysis and interpretation. TI, HK, and YAo wrote the first draft of the
- 429 manuscript. All other authors critically reviewed the manuscript for intellectual content.
- 430 All authors read and approved the final version of the manuscript.

432 References

- 433 1. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global
- 434 epidemiology of Duchenne muscular dystrophy: An updated systematic review and
- 435 meta-analysis. Orphanet J Rare Dis. 2020;15(1):141.
- 436 2. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al.
- 437 The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An
- 438 evidence review. Orphanet J Rare Dis. 2017;12(1):79.
- 439 3. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et
- 440 al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis,
- 441 and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional
- 442 management. Lancet Neurol. 2018;17(3):251–67.
- 443 4. Giliberto F, Radic CP, Luce L, Ferreiro V, de Brasi C, Szijan I. Symptomatic
- female carriers of Duchenne muscular dystrophy (DMD): Genetic and clinical
- 445 characterization. J Neurol Sci. 2014;336(1-2):36–41.
- 446 5. Archer JE, Gardner AC, Roper HP, Chikermane AA, Tatman AJ. Duchenne
- 447 muscular dystrophy: The management of scoliosis. J Spine Surg. 2016;2(3):185–94.
- 448 6. Adorisio R, Mencarelli E, Cantarutti N, Calvieri C, Amato L, Cicenia M, et al.

449 Duchenne dilated cardiomyopathy: Cardiac management from prevention to advanced

- 450 cardiovascular therapies. J Clin Med. 2020;9(10):3186.
- 451 7. Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne
- 452 muscular dystrophy. Nat Rev Neurol. 2019;15(7):373–86.
- 453 8. Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y. Anti-inflammatory drugs
- 454 for Duchenne muscular dystrophy: Focus on skeletal muscle-releasing factors. Drug
- 455 Des Devel Ther. 2016;10:2745–58.
- 456 9. Werneck LC, Lorenzoni PJ, Ducci RD, Fustes OH, Kay CSK, Scola RH.
- 457 Duchenne muscular dystrophy: An historical treatment review. Arq Neuropsiquiatr.
- 458 2019;77(8):579–89.
- 459 10. Sun C, Shen L, Zhang Z, Xie X. Therapeutic strategies for Duchenne muscular
- 460 dystrophy: An update. Genes (Basel). 2020;11(8):837.
- 461 11. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al.
- 462 Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory,
- 463 cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347-

464 61.

465 12. Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for

466 Duchenne muscular dystrophy. Gene Ther. 2020;27(9):407–16.

- 467 13. Echevarria L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne
- 468 muscular dystrophy. Hum Mol Genet. 2018;27(R2):R163–72.
- 469 14. Nakamura A. Mutation-based therapeutic strategies for Duchenne muscular
- 470 dystrophy: From genetic diagnosis to therapy. J Pers Med. 2019;9(1):16.
- 471 15. US Food and Drug Administration. FDA grants accelerated approval to first
- 472 drug for Duchenne muscular dystrophy. 19 September 2016.
- 473 https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-
- 474 approval-first-drug-duchenne-muscular-dystrophy. Accessed 16 March 2021.
- 475 16. US Food and Drug Administration. FDA grants accelerated approval to first
- 476 targeted treatment for rare Duchenne muscular dystrophy mutation. 12 December
- 477 2019. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-
- 478 approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation.
- 479 Accessed 16 March 2021.
- 480 17. US Food and Drug Administration. FDA approves targeted treatment for rare
- 481 Duchenne muscular dystrophy mutation. 12 August 2020. https://www.fda.gov/news-
- 482 events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-

483 muscular-dystrophy-mutation. Accessed 16 March 2021.

- 484 18. Dhillon S. Viltolarsen: First approval. Drugs. 2020;80(10):1027–31.
- 485 19. Watanabe N, Nagata T, Satou Y, Masuda S, Saito T, Kitagawa H, et al. NS-
- 486 065/NCNP-01: An antisense oligonucleotide for potential treatment of exon 53 skipping
- 487 in Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2018;13:442–9.
- 488 20. Lim KRQ, Nguyen Q, Yokota T. Genotype-phenotype correlations in Duchenne
- and Becker muscular dystrophy patients from the Canadian neuromuscular disease
- 490 registry. J Pers Med. 2020;10(4):241.
- 491 21. Komaki H, Takeshima Y, Matsumura T, Ozasa S, Funato M, Takeshita E, et al.
- 492 Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study. Ann
- 493 Clin Transl Neurol. 2020;7(12):2393–408.
- 494 22. Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al.
- 495 Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular
- 496 dystrophy amenable to exon 53 skipping: A phase 2 randomized clinical trial. JAMA
- 497 Neurol. 2020;77(8):982–91.
- 498 23. NS Pharma Inc. Study to assess the efficacy and safety of viltolarsen in
- ambulant boys with DMD (RACER53). ClinicalTrials.gov Identifier: NCT04060199.

500 https://clinicaltrials.gov/ct2/show/NCT04060199. Accessed 16 March 2021.

- 501 24. Findlay AR, Wein N, Kaminoh Y, Taylor LE, Dunn DM, Mendell JR, et al.
- 502 Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45.
- 503 Ann Neurol. 2015;77(4):668–74.
- 504 25. Catherine LB, David S, Soledad M, Maria EF, Kyriaki K, Konstantina K, et al.
- 505 The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne
- 506 muscular dystrophy mutations. Hum Mutat. 2015;36(4):395-402
- 507 26. Straub V, Mercuri E, DMD outcome measure study group. Report on the
- 508 workshop: Meaningful outcome measures for Duchenne muscular dystrophy, London,
- 509 UK, 30-31 January 2017. Neuromuscul Disord. 2018;28(8):690–701.
- 510 27. Takase M, Sakata H, Shikata M, Tatara K, Fukushima W, Yoshi T, et al.
- 511 Preparation of spirometry standards for Japanese children (final report) Journal of the
- 512 Japanese Society of Pediatric Respiratory Diseases. 2008;19(2):164–76. [In
- 513 Japanese].
- 514 28. Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, et al.
- 515 Development of a functional assessment scale for ambulatory boys with Duchenne
- 516 muscular dystrophy. Physiother Res Int. 2012;17(2):101–9.

- 517 29. Nesbitt D, Molina SL, Cattuzzo MT, Robinson LE, Phillips D, Stodden D.
- 518 Assessment of a Supine-to-Stand (STS) task in early childhood: A measure of
- 519 functional motor competence. J Mot Learn Devel. 2017;5:252–66.
- 520 30. Watson MJ. Refining the ten-metre walking test for use with neurologically
- 521 impaired people. Physiother. 2002;88(7):386–97.
- 522 31. ATS committee on proficiency standards for clinical pulmonary function
- 523 laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit
- 524 Care Med. 2002;166(1):111–7.
- 525 32. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and

526 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed).

- 527 1982;284(6329):1607-8.
- 528 33. Podsiadlo D, Richardson S. The timed "Up & Go": A test of basic functional
- 529 mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.
- 530 34. Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, et al.
- 531 Development of the Performance of the Upper Limb module for Duchenne muscular
- 532 dystrophy. Dev Med Child Neurol. 2013;55(11):1038–45.
- 533 35. Takizawa H, Hara Y, Mizobe Y, Ohno T, Suzuki S, Inoue K, et al. Modelling

534 Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-

- 535 deazaneplanocin A hydrochloride. Sci Rep. 2019;9(1):3807.
- 536 36. Takizawa H, Takeshita E, Sato M, Shimizu-Motohashi Y, Ishiyama A, Mori-
- 537 Yoshimura M, et al. Highly sensitive screening of antisense sequences for different
- types of DMD mutations in patients' urine-derived cells. J Neurol Sci. 2021;423:117337.
- 539 37. Sato M, Takizawa H, Nakamura A, Turner BJ, Shabanpoor F, Aoki Y.
- 540 Application of urine-derived stem cells to cellular modeling in neuromuscular and
- neurodegenerative diseases. Front Mol Neurosci. 2019;12:297.
- 542 38. Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N, et
- 543 al. Biochemical characterization of patients with in-frame or out-of-frame DMD
- deletions pertinent to exon 44 or 45 skipping. JAMA Neurol. 2014;71(1):32–40.
- 545 39. Aartsma-Rus A, Muntoni F. 194th ENMC international workshop. 3rd ENMC
- 546 workshop on exon skipping: towards clinical application of antisense-mediated exon
- 547 skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The
- 548 Netherlands. Neuromuscul Disord. 2013;23(11):934–44.
- 549 40. Dwianingsih EK, Malueka RG, Nishida A, Itoh K, Lee T, Yagi M, et al. A novel 550 splicing silencer generated by DMD exon 45 deletion junction could explain upstream

exon 44 skipping that modifies dystrophinopathy. J Hum Genet. 2014;59(8):423–9.

- 552 41. Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D'Amico A, et al. Long-
- term natural history data in Duchenne muscular dystrophy ambulant patients with
- 554 mutations amenable to skip exons 44, 45, 51 and 53. PLoS One.
- 555 2019;14(6):e0218683.
- 556 42. van den Bergen JC, Ginjaar HB, Niks EH, Aartsma-Rus A, Verschuuren JJ.
- 557 Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44
- skipping. J Neuromuscul Dis. 2014;1(1):91–4.
- 43. Wang RT, Barthelemy F, Martin AS, Douine ED, Eskin A, Lucas A, et al. DMD
- 560 genotype correlations from the Duchenne Registry: Endogenous exon skipping is a
- 561 factor in prolonged ambulation for individuals with a defined mutation subtype. Hum
- 562 Mutat. 2018;39(9):1193–202.

563

564

565

566

568	
569	
570	
571	
572	
573	
574	
575	
576	
577	Tables
578	Table 1 Criteria to determine whether to proceed to the next dose level and study part
	Procedures for transition Criteria to be considered

Transition of dose level in Part 1

- The Safety Monitoring 1) An ADR of Grade \geq 3 in at least 1 subject • Committee will determine if the study proceeds to the next dose subjects^a level
- The decision will be made

following treatment of the third

subject at each dose level

The evaluated data will include all treated subjects at the current dose level obtained by Day 7 after the second administration of NS-089/NCNP-02

- 2) Any of the following criteria in at least 2
 - ALT ≥ 10 × ULN and total bilirubin ≥ 2 ×

ULN

- ALT ≥ 10 × ULN and PT-INR > 1.5
- ALT > 2 × baseline value and total

bilirubin > $2 \times ULN$

ALT > 2 × baseline value and PT-INR >

1.5

ALT ≥ 10 × ULN plus symptoms of

hepatitis or hypersensitivity

Urinary P/C ratio > 0.5 g/gCr on two

consecutive measurements

Cystatin C concentration > ULN and \geq

1.5 × baseline value

• 24-hour pooled urine protein > 300

mg/day and > $2 \times$ baseline value

• 24-hour pooled urine albumin > 50

mg/day and > 2 × baseline value

• At least one new non-hyaline cast/LPF

or at least 21 new hyaline casts/LPF in

urinary sediment

• New appearance of RBCs > 5/HPF in

urinary sediment

Transition from Part 1 to Part 2

The Safety Monitoring The determination will be made considering
 Committee will consider whether the following items:
 the study proceeds to Part 2 and
 The nature of the AEs found in Part 1
 the doses to be used therein,
 The causal relationship of the AEs with and the investigator will make the study drug (NS-089/NCNP-02)
 the determination.
 Dose dependency of the toxicities

	following treatment of the third		observed
	subject at the highest dose	•	AE severity
	among the doses evaluated in	•	AE reversibility
	Part 1		
		•	PK data
•	The evaluated data will include		
	all treated subjects at the	•	Nonclinical toxicity study findings
	highest dose level obtained by		
	Day 7 after the second		
	administration of NS-089/NCNP-		
	02		

- 579 Abbreviations: ADR, adverse drug reaction; AE, adverse event; ALT, alanine
- 580 aminotransferase; HPF, high power field; LPF, low power field; P/C, protein/creatinine;
- 581 PK, pharmacokinetic; PT-INR, prothrombin time-international normalized ratio; RBC,
- 582 red blood cell; ULN, upper limit of normal.
- ^aBaseline values, and other clinical findings and laboratory test data, will be taken into
- 584 consideration by the Safety Monitoring Committee when evaluating the relevance of
- 585 ADRs.

586					
587					
588					
589					
590					
591					
592					
593					
594					
595					
596					
597					
598					
599	Table 2 Labo	pratory test meas	sures		
	Test		Parameter		

Hematology	RBC, hemoglobin, hematocrit, reticulocytes, MCV, MCH,
	MCHC, WBC, platelet count, WBC differential
	(neutrophil, eosinophil, basophil, monocyte,
	lymphocyte), fibrinogen, aPTT, and PT-INR
Blood chemistry	Na, K, Ca, Cl, inorganic P, BUN, creatinine, cystatin C,
	AST, ALT, GGT, ALP, haptoglobin, LDH, CK/CK-MB/CK-
	MM, total bilirubin, direct bilirubin, cardiac troponin T,
	BNP, total protein, albumin, A/G ratio, total cholesterol,
	triglyceride, blood glucose, uric acid, and CRP
Urinalysis	Glucose, occult blood, urobilinogen, specific gravity,
	osmotic pressure, sediment (red blood cell, white blood
	cell, cast), protein (CBB method) ^a , albumin ^a , NAG ^a , α_1 -
	microglobulin ^a , creatinine ^a , Na ^a , K ^a , Cl ^a , inorganic P ^a ,
	and β_2 -microglobulin ^a
Cytokine/complement	IL-6, TNF-α, MCP-1, CH50, C3, and C4
levels	

^aMeasurements were conducted using 24-hour pooled urine on Days 2, 4, and 11 of

601 Part 1, and Days 2 and 163 of Part 2.

602	Abbreviations: A/G	albumin/globulin; AL	P, alkaline	phosphatase;	ALT, alanine
-----	--------------------	----------------------	-------------	--------------	--------------

- aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate
- aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; C3/C4,
- 605 complement proteins 3 and 4; CBB, Coomassie brilliant blue; CH50, 50% hemolytic
- 606 complement; CK creatine kinase (CK-MB, heart isoenzyme; CK-MM, muscle and heart
- 607 isoenzyme); CRP, C-reactive protein; GGT, gamma-glutamyl transpeptidase; IL,
- 608 interleukin; LDH, lactate dehydrogenase; MCH, mean corpuscular hemoglobin; MCHC,
- 609 mean corpuscular hemoglobin concentration; MCP-1, monocyte chemoattractant
- 610 protein-1; MCV, mean corpuscle volume; NAG, N-acetyl-β-D-glucosaminidase; PT-INR,
- 611 prothrombin time-international normalized ratio; RBC, red blood cells; TNF, tumor
- 612 necrosis factor; WBC, white blood cells.

613

614

616 Figure legends

- 617 Figure 1 Study design and flow
- 618 In Part 1, the dose of NS-089/NCNP-02 will be escalated in a stepwise manner from
- Level 1 (1.62 mg/kg QW) to Level 4 (80 mg/kg QW). A total of four doses will be
- 620 intravenously administered to two cohorts consisting of three subjects each, and each
- 621 cohort will receive two doses. In Part 2, two doses of NS-089/NCNP-02 (determined
- from the results of Part 1) will be intravenously administered once weekly for 24 weeks.
- 623 Abbreviation: QW, once weekly.
- 624
- 625 **Figure 2** Study observations and examinations: implementation schedules. **a**: Part 1;
- 626 **b**: Part 2
- ^aPatients who complete Level 1 or 2 and proceed to Level 3 or 4 will not have a pre-
- 628 treatment observation period prior to the administration at Level 3 or 4, but will have
- 629 their height/weight measured during the period between Days -7 and -1 before
- 630 administration of NS-089/NCNP-02.
- ^bConsent may be obtained before the day of interim enrollment.
- 632 ^cInterim enrollment. After obtaining informed consent, the investigator or sub-

- 633 investigator will confirm that the patient is a candidate for exon 44 skipping treatment
- and enroll the patient. The results of exon 44 sequence analysis shall be confirmed
- 635 before formal enrollment.
- ^dFormal enrollment. Patients will be enrolled after confirming examination results
- 637 obtained within 14 days before the start of administration of NS-089/NCNP-02. Formal
- 638 enrollment on the day before the first administration may be accepted.
- ^eTo be performed at the end of administration and at 2 hours after the end of
- 640 administration.
- ⁶⁴¹ ^fTo be performed at the following times: 30 minutes after the start of administration on
- Day 1; at the end of administration on Day 1; at 1, 2, 4, and 6 hours after the end of
- administration on Day 1; at the end of administration on Day 8; and at 1 hour after the
- 644 end of administration on Day 8.
- ⁹For Part 1, the results of hepatitis B antigen, hepatitis C antibody, and human
- 646 immunodeficiency virus antibody tests must be confirmed by the day of formal
- 647 enrollment; such tests will not be performed post-treatment for Part 1 and pre-treatment

648 for Part 2.

^hTo be performed at Levels 3 and 4.

- ⁱMuscle and skin samples will be taken simultaneously with muscle biopsy. Urine
- samples will be collected at Part2, if it could not be collected in a pre-treatment
- observation period at Part 1.
- ^jTo be performed after implementing motor function assessment and confirming the
- muscle tissue to be sampled by MRI. In addition, this is to be performed before the
- start of administration (pre-treatment for Part 1). Subjects will be admitted at the time of
- 656 muscle biopsy.
- ⁶⁵⁷ ^kIn Part 1, the motor function assessment will be performed between Days –28 and –1.
- In Parts 1 and 2, the 2-minute walk test will be conducted on a different day from other
- 659 motor function parameters.
- ⁶⁶⁰ ¹To be performed 30 minutes after the start of administration, at the end of
- administration, and at 15 minutes, and 1, 2, 4, and 8 hours after the end of
- 662 administration.
- ^mTo be performed 23 hours after the end of administration.
- ⁿTo be performed before administration.
- ^oTo be performed on Day169 or 176.
- ^pTo be performed at the end of administration and 1 hour after the end of

667 administration.

- ^qMuscle sample is collected at the same time as muscle biopsy.
- 669 Abbreviations: ECG, electrocardiogram; MRI, magnetic resonance imaging.

670



Figure 2a

5																					
Parameter	r	Pre-trea	tment ^a	Treatment															Post-tre	atment	
Week		-12	-1					1						_	2	2				3	4
Day (rang	e)	-84 to -14	-7 to -1	(±	1 0)	2 (± 0)	3 (± 0)	4 (± 0)	5 (± 0)	6 (± 0)	7 (± 0)	8 (± 0)		9 (± 0)	10 (± 0)	11 (± 0)	12 (± 0)	13 (± 0)	14 (± 0)	15 (± 2)	22 (± 2)
Inpatient		No	Yes			Yes		-		No				Yes				No		No	No
Pre- or po	st-administration			Pre	Post							Pre	Post								
Informed of	consent	●b			-																
Enrollmen	t	●c		●d																	
Study drug	g administration				•								•								
ics	Age/sex/race	٠																			
graph	Medical History	•	•																		
demo	Height/weight	٠	●a																	•	
tient o	Concomitant drugs	٠	•		•	•	•	•				•	•	•	•	٠				•	•
Ра	Inclusion/exclusion criteria	٠		•								•									
ion	Physical examination	٠	•	•	● ^e	•		•				•	● ^e	•		•				•	•
/aluat	Vital signs	٠	•	•	● ^e	•		•				•	● ^e	•		•				•	•
ety ev	12-lead ECG	•	-	•	●f	•		•				•	●f	•		•				•	•
Saf	Echocardiography	•		•								•									
	Dystrophin gene	•																			
	Hematology/blood chemistry	٠		•		•		•				•		•		٠				•	•
	Immunology	●g																		●g	
tests	MRI	•																			
atory	Pulmonary function	•																			
Labor	Urinalysis	•		•		•		•				•		•		•				•	•
	Cytokine/complement levels	٠		•	● ^e	•						•	● ^e	•							
	Urine cytology		-	● ^h																● ^h	
	In vitro assay	•	i																		
tion	Muscle biopsy	•	j																		
evalua	Motor function assessment	۰	<				_														
acy e	Plasma drug concentration			•	●I	● ^m						•		● ^m						•	•
Effic	Urinary drug concentration					•						•									
				-		-		-							-						

Figure 2b

Parameter	r	Pre- treatment		Treatment																					
Week -2 1		1		2	3	4	5/ 6/ 7	8	9/ 10/ 11		12		13/ 14/ 15	16	17/ 18/ 19	20	21/ 22/ 23	24			25	26			
Day (range)		-14 to -1	(±	1 ± 0)	2 (±0)	8 (± 2)	15 (± 2)	22 (± 2)	29/ 36/ 43 (± 2)	50 (± 2)	57/ 64/ 71 (± 2)	(:	78 ± 2)	79	85/ 92/ 99 (± 2)	106 (± 2)	113/1 20/12 7 (± 2)	134 (± 2)	141/1 48/15 5 (± 2)	162 (± 2)		163	169 (± 2)	176 (± 2)	
Inpatient		No		Yes				N	lo				Yes				No			Yes			yes		
Pre- or pos	st-administration		Pre	Post		Pre Post			Pre	Post															
Study drug	g administration			•		•	•	•	•	•	•		•		•	•	•	•	•		•				
ent aphics	Height/weight	•																					•	0	
Pati demogr	Concomitant drugs	•		•	•	•	•	•	•	•	•		•		•	۲	•	•	•		•	•	•	0	
	Physical examination	•	٠	● ^e	•	●n	●n	●n	●n	●n	●n	٠			●n	●n	●n	●n	●n	•	●e	•	•	0	
valuation	Vital signs	•	•	● ^e	•	● ⁿ	● ⁿ	● ⁿ	● ⁿ	● ⁿ	● ⁿ	•	●e		● ⁿ	●n	●n	●n	●n	•	●e	•	•	0	
Safety ev	12-lead ECG	•	•	●p	•			●n		●n		•	●p			●n		● ⁿ		•	●p	•	• ⁰		
	Echocardiography	•																					•°		
	Hematology/ blood chemistry	•	•		•			●n		●n		•				●n		●n		•			•	0	
	Immunology	●g																					•	0	
	MRI	•																					•	0	
/ tests	Pulmonary function	•																					•	0	
aborator	Urinalysis	•	•		•			● ⁿ		● ⁿ		•				● ⁿ		● ⁿ		٠		•	•	0	
	Cytokine/ complement levels		•	●e	•							•	●e	•						•	●e	•			
	Urine cytology		•																				•	0	
	In vitro assay	●i																					●C	● ^{0, q}	
	Muscle biopsy																						€	, 0	
svaluation	Motor function assessment	●k											●k										۰	i, 0	
Efficacy e	Plasma drug concentration		•	●I	●m	●n		●n		●n		•				●n		●n		•	●I	●m	● ^r	i, O	
	Urinary drug concentration				•																	•			